Virtual Library
Start Your Search
Y. Wu
Author of
-
+
P1.02 - Poster Session with Presenters Present (ID 454)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.02-017 - Relative Abundance of EGFR Mutations Predict Tumor Metastasis and EGFR-TKIs Prognosis in Patients with Non-Small Cell Lung Cancer (ID 4525)
14:30 - 14:30 | Author(s): Y. Wu
- Abstract
Background:
The most lethality in NSCLC is due to uncontrolled tumor metastasis. Epidermal growth factor receptor (EGFR) has been confirmed to be an effective biomarker in EGFR-TKIs treatment for advanced NSCLC. Previous studies have demonstrated EGFR mutation abundance could predict benefit from EGFR-TKIs treatment. However, there is no investigation on the correlation between EGFR mutation abundance and tumor metastasis. Here we aimed to explore potential effect of EGFR mutation abundance on tumor metastasis and EGFR-TKIs prognosis.
Methods:
3913 patients from Henan Cancer Hospital diagnosed with NSCLC were enrolled. The EGFR mutation abundance in tumor specimens was quantified by amplification refractory mutation system (ARMS). Above 10% was defined as high abundance, and below 10% was defined as low abundance.
Results:
The ratio of high mutation abundance in age < 60 years group was significantly higher than that in age ≥ 60 years group (55.4% vs. 42.5%, P=0.000), similar distribution was also detected in 19 exon deletion and L858R subgroup (P=0.003 and 0.030, respectively). Whereas the distribution of EGFR mutation abundance was no difference between surgery and biopsy specimens (P=1.000). Additionally, the ratio of high abundance in 19 exon deletion was obviously higher than that in L858R and rare mutations (66.5% vs. 31.6% vs. 51.1%, P=0.000). Meanwhile, the ratio of high abundance in patients with hepar metastasis was significantly higher than that in patients without hepar metastasis (57.2% vs. 47.8%, P=0.036), but that in brain or bone metastasis was demonstrated no significant difference (P=0.897 and P=0.293, respectively). The subgroup analysis among above metastasis patients indicated the ratio of high abundance in 19 exon deletion was significantly higher that in L858R. Furthmore, the difference in median PFS between 19 exon deletion and L858R group was significant (17.5 months vs. 9.2 months, P=0.003).
Conclusion:
EGFR mutation abundance was not associated with the methods of collecting specimens. The younger patients more likely harbor high EGFR mutation abundance. Hepar metastasis status was associated with EGFR mutation abundance. Median PFS in 19 exon deletion patients was notablely longer than that in L858R group for EGFR-TKIs treatment, which may refer to high abundance in 19 exon deletion.
